View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 24, 2011

FDA approves Medtronic continuous glucose monitoring system

Medtronic has received US Food and Drug Administration (FDA) approval for its iPro2, a next-generation continuous glucose monitoring system.

Medtronic has received US Food and Drug Administration (FDA) approval for its iPro2, a next-generation continuous glucose monitoring system.

The iPro2 device allows physicians to reveal hypoglycaemic and hyperglycaemic glucose excursions can lead to dangerous health complications in patients with diabetes.

The system will help identify nocturnal hypoglycaemic or hyperglycaemic following meals, allowing users to make therapy adjustments that can result in better glucose control.

iPro2 records and stores up to 288 glucose readings a day, and provides clinicians with an insight into how diet, medication and daily activities affect their patients’ glucose levels.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management